The Experts below are selected from a list of 1161 Experts worldwide ranked by ideXlab platform
Akiyoshi Nishikawa - One of the best experts on this subject based on the ideXlab platform.
-
Sesamin a lignan of sesame down regulates cyclin d1 protein expression in human tumor cells
Cancer Science, 2007Co-Authors: Tomoya Yokota, Youichirou Matsuzaki, Mayumi Kawanaka, Masako Enokikonishi, Junko Takayasu, Makoto Koyama, Toshiaki Hitomi, Yusuke Okuyama, Hoyoku Nishino, Akiyoshi NishikawaAbstract:Sesamin is a major lignan constituent of sesame and possesses multiple functions such as antihypertensive, cholesterol-lowering, lipid-lowering and anticancer activities. Several groups have previously reported that Sesamin induces growth inhibition in human cancer cells. However, the nature of this growth inhibitory mechanism remains unknown. The authors here report that Sesamin induces growth arrest at the G1 phase in cell cycle progression in the human breast cancer cell line MCF-7. Furthermore, Sesamin dephosphorylates tumor-suppressor retinoblastoma protein (RB). It is also shown that inhibition of MCF-7 cell proliferation by Sesamin is correlated with down-regulated cyclin D1 protein expression, a proto-oncogene that is overexpressed in many human cancer cells. It was found that Sesamin-induced down-regulation of cyclin D1 was inhibited by proteasome inhibitors, suggesting that Sesamin suppresses cyclin D1 protein expression by promoting proteasome degradation of cyclin D1 protein. Sesamin down-regulates cyclin D1 protein expression in various kinds of human tumor cells, including lung cancer, transformed renal cells, immortalized keratinocyte, melanoma and osteosarcoma. Furthermore, depletion of cyclin D1 protein using small interfering RNA rendered MCF-7 cells insensitive to the growth inhibitory effects of Sesamin, implicating that cyclin D1 is at least partially related to the antiproliferative effects of Sesamin. Taken together, these results suggest that the ability of Sesamin to down-regulate cyclin D1 protein expression through the activation of proteasome degradation could be one of the mechanisms of the antiproliferative activity of this agent. (Cancer Sci 2007; 98: 1447–1453)
-
Sesamin a lignan of sesame down regulates cyclin d1 protein expression in human tumor cells
Cancer Science, 2007Co-Authors: Tomoya Yokota, Youichirou Matsuzaki, Mayumi Kawanaka, Masako Enokikonishi, Junko Takayasu, Makoto Koyama, Toshiaki Hitomi, Yusuke Okuyama, Hoyoku Nishino, Akiyoshi NishikawaAbstract:Sesamin is a major lignan constituent of sesame and possesses multiple functions such as antihypertensive, cholesterol-lowering, lipid-lowering and anticancer activities. Several groups have previously reported that Sesamin induces growth inhibition in human cancer cells. However, the nature of this growth inhibitory mechanism remains unknown. The authors here report that Sesamin induces growth arrest at the G1 phase in cell cycle progression in the human breast cancer cell line MCF-7. Furthermore, Sesamin dephosphorylates tumor-suppressor retinoblastoma protein (RB). It is also shown that inhibition of MCF-7 cell proliferation by Sesamin is correlated with down-regulated cyclin D1 protein expression, a proto-oncogene that is overexpressed in many human cancer cells. It was found that Sesamin-induced down-regulation of cyclin D1 was inhibited by proteasome inhibitors, suggesting that Sesamin suppresses cyclin D1 protein expression by promoting proteasome degradation of cyclin D1 protein. Sesamin down-regulates cyclin D1 protein expression in various kinds of human tumor cells, including lung cancer, transformed renal cells, immortalized keratinocyte, melanoma and osteosarcoma. Furthermore, depletion of cyclin D1 protein using small interfering RNA rendered MCF-7 cells insensitive to the growth inhibitory effects of Sesamin, implicating that cyclin D1 is at least partially related to the antiproliferative effects of Sesamin. Taken together, these results suggest that the ability of Sesamin to down-regulate cyclin D1 protein expression through the activation of proteasome degradation could be one of the mechanisms of the antiproliferative activity of this agent.
Tomoya Yokota - One of the best experts on this subject based on the ideXlab platform.
-
Sesamin a lignan of sesame down regulates cyclin d1 protein expression in human tumor cells
Cancer Science, 2007Co-Authors: Tomoya Yokota, Youichirou Matsuzaki, Mayumi Kawanaka, Masako Enokikonishi, Junko Takayasu, Makoto Koyama, Toshiaki Hitomi, Yusuke Okuyama, Hoyoku Nishino, Akiyoshi NishikawaAbstract:Sesamin is a major lignan constituent of sesame and possesses multiple functions such as antihypertensive, cholesterol-lowering, lipid-lowering and anticancer activities. Several groups have previously reported that Sesamin induces growth inhibition in human cancer cells. However, the nature of this growth inhibitory mechanism remains unknown. The authors here report that Sesamin induces growth arrest at the G1 phase in cell cycle progression in the human breast cancer cell line MCF-7. Furthermore, Sesamin dephosphorylates tumor-suppressor retinoblastoma protein (RB). It is also shown that inhibition of MCF-7 cell proliferation by Sesamin is correlated with down-regulated cyclin D1 protein expression, a proto-oncogene that is overexpressed in many human cancer cells. It was found that Sesamin-induced down-regulation of cyclin D1 was inhibited by proteasome inhibitors, suggesting that Sesamin suppresses cyclin D1 protein expression by promoting proteasome degradation of cyclin D1 protein. Sesamin down-regulates cyclin D1 protein expression in various kinds of human tumor cells, including lung cancer, transformed renal cells, immortalized keratinocyte, melanoma and osteosarcoma. Furthermore, depletion of cyclin D1 protein using small interfering RNA rendered MCF-7 cells insensitive to the growth inhibitory effects of Sesamin, implicating that cyclin D1 is at least partially related to the antiproliferative effects of Sesamin. Taken together, these results suggest that the ability of Sesamin to down-regulate cyclin D1 protein expression through the activation of proteasome degradation could be one of the mechanisms of the antiproliferative activity of this agent. (Cancer Sci 2007; 98: 1447–1453)
-
Sesamin a lignan of sesame down regulates cyclin d1 protein expression in human tumor cells
Cancer Science, 2007Co-Authors: Tomoya Yokota, Youichirou Matsuzaki, Mayumi Kawanaka, Masako Enokikonishi, Junko Takayasu, Makoto Koyama, Toshiaki Hitomi, Yusuke Okuyama, Hoyoku Nishino, Akiyoshi NishikawaAbstract:Sesamin is a major lignan constituent of sesame and possesses multiple functions such as antihypertensive, cholesterol-lowering, lipid-lowering and anticancer activities. Several groups have previously reported that Sesamin induces growth inhibition in human cancer cells. However, the nature of this growth inhibitory mechanism remains unknown. The authors here report that Sesamin induces growth arrest at the G1 phase in cell cycle progression in the human breast cancer cell line MCF-7. Furthermore, Sesamin dephosphorylates tumor-suppressor retinoblastoma protein (RB). It is also shown that inhibition of MCF-7 cell proliferation by Sesamin is correlated with down-regulated cyclin D1 protein expression, a proto-oncogene that is overexpressed in many human cancer cells. It was found that Sesamin-induced down-regulation of cyclin D1 was inhibited by proteasome inhibitors, suggesting that Sesamin suppresses cyclin D1 protein expression by promoting proteasome degradation of cyclin D1 protein. Sesamin down-regulates cyclin D1 protein expression in various kinds of human tumor cells, including lung cancer, transformed renal cells, immortalized keratinocyte, melanoma and osteosarcoma. Furthermore, depletion of cyclin D1 protein using small interfering RNA rendered MCF-7 cells insensitive to the growth inhibitory effects of Sesamin, implicating that cyclin D1 is at least partially related to the antiproliferative effects of Sesamin. Taken together, these results suggest that the ability of Sesamin to down-regulate cyclin D1 protein expression through the activation of proteasome degradation could be one of the mechanisms of the antiproliferative activity of this agent.
Yoshinobu Kiso - One of the best experts on this subject based on the ideXlab platform.
-
the mechanism underlying the synergetic hypocholesterolemic effect of Sesamin and α tocopherol in rats fed a high cholesterol diet
Journal of Pharmacological Sciences, 2011Co-Authors: Tomohiro Rogi, Yoshiko Ono, Namino Tomimori, Yoshinobu KisoAbstract:Sesamin is a major lignan in sesame seed. We confirmed that ingestion of Sesamin and α-tocopherol synergistically reduced the concentration of blood cholesterol in rats given a high-cholesterol diet. To elucidate the molecular mechanism behind this effect, we analyzed the gene-expression profiles in rat liver after co-ingestion of Sesamin and α-tocopherol. Six-week-old male Sprague-Dawley rats were fed a 1% cholesterol diet (HC) or HC containing 0.2% Sesamin, 1% α-tocopherol or Sesamin + α-tocopherol for 10 days. Blood samples were collected on days 1, 3, 7, and 10 and livers were excised on day 10. The gene expressions of ATP-binding cassette, sub-family G (WHITE), members 5 (ABCG5) and 8 (ABCG8) were significantly increased, while the gene expression of apolipoprotein (Apo) A4 was significantly decreased. ABCG5 and ABCG8 form a functional heterodimer that acts as a cholesterol efflux transporter, which contributes to the excretion of cholesterol from the liver. ApoA4 controls the secretion of ApoB, which is a component of low-density-lipoprotein cholesterol. These studies indicate that the cholesterol-lowering mechanism underlying the effects of co-ingestion of Sesamin and α-tocopherol might be attributable to increased biliary excretion of cholesterol and reduced ApoB secretion into the bloodstream.
-
antihypertensive effects of Sesamin in humans
Journal of Nutritional Science and Vitaminology, 2009Co-Authors: Takashi Miyawaki, Yoshinobu Kiso, Hideshi Aono, Yoshiko Toyodaono, Hirofumi Maeda, Kenji MoriyamaAbstract:Sesamin, one of the lignans contained in sesame, has been considered to have medicinal effects. It has been reported that Sesamin suppressed the development of hypertension in rats. In this study, using a double-blind, cross-over, placebo-controlled trial, we investigated the effect of 4-wk administration of Sesamin on blood pressure (BP) in mildly hypertensive humans. Twenty-five middle-aged subjects with mild hypertension were divided into two groups, matched by age and body mass index. Twelve subjects were allocated to 4-wk intake of capsules with 60 mg Sesamin per day and 13 subjects to 4-wk intake of a placebo (period 1). After a 4-wk washout period, the subjects received the alternative administration for 4 wk (period 2). BP decreased with statistical significance with the administration of Sesamin (systolic: 137.6±2.2 to 134.1±1.7 mmHg, p=0.044, diastolic: 87.7±1.3 to 85.8±1.0 mmHg, p=0.045), but little changed with the placebo (systolic: 135.0±1.8 to 135.1±1.7 mmHg, diastolic: 85.9±1.2 to 86.6±1.2 mmHg). In conclusion, 4-wk administration of 60 mg Sesamin significantly decreased BP by an average of 3.5 mmHg systolic BP and 1.9 mmHg diastolic BP. These results suggest that Sesamin has an antihypertensive effect in humans. Epidemiological studies suggested that a 2-3 mmHg decrease in BP reduces the rate of cardiovascular diseases; therefore, it is considered that BP reduction achieved by Sesamin may be meaningful to prevent cardiovascular diseases.
-
dietary Sesamin suppresses aortic nadph oxidase in doca salt hypertensive rats
Clinical and Experimental Pharmacology and Physiology, 2008Co-Authors: Daisuke Nakano, Yoshinobu Kiso, Daisuke Kurumazuka, Yukiko Nagai, Akira Nishiyama, Yasuo MatsumuraAbstract:1. Dietary Sesamin, a sesame lignan, is known to suppress the development of experimental hypertension in rats partly through its inhibitory effect on vascular O(2)(-) production. Therefore, in the present study, we examined whether Sesamin feeding had any effect on vascular NADPH oxidase using aortas from deoxycorticosterone acetate (DOCA) salt hypertensive rats. 2. After a 5 week feeding and treatment period, aortic O(2)(-) production and NADPH oxidase activity were measured using the lucigenin assay. Reverse transcription-polymerase chain reaction was performed to analyse aortic expression of NADPH oxidase subunit (p22phox, gp91phox, Nox1 and Nox4) mRNA. 3. Sesamin feeding markedly suppressed DOCA salt-induced hypertension and significantly decreased aortic O(2)(-) production. DOCA salt treatment increased NADPH oxidase activity and elevated aortic mRNA expression of p22phox, gp91phox, Nox1 and Nox4. Sesamin feeding abolished the increase in NADPH oxidase activity and, furthermore, significantly suppressed increases in p22phox, gp91phox and Nox1 mRNA expression. 4. In conclusion, dietary Sesamin prevented DOCA salt-induced increases in NADPH oxidase activity and subunit mRNA expression. These effects seem to be involved in the anti-oxidant and antihypertensive effects of Sesamin.
-
modulating effect of Sesamin a functional lignan in sesame seeds on the transcription levels of lipid and alcohol metabolizing enzymes in rat liver a dna microarray study
Bioscience Biotechnology and Biochemistry, 2005Co-Authors: Nobuo Tsuruoka, Ayako Kidokoro, Ichiro Matsumoto, Keiko Abe, Yoshinobu KisoAbstract:Sesamin, a major lignan in sesame seeds, has multiple functions such as cholesterol-lowering and anti-hypertensive activities. To investigate the effect of Sesamin on gene expression in the liver, a DNA microarray analysis was carried out. The ingestion of Sesamin dissolved in olive oil up-regulated the expression of 38 genes, 16 of which encode proteins possessing a lipid-metabolizing function, and 16 of which encode proteins possessing a xenobiotic/endogenous substance metabolizing function. In particular, Sesamin significantly increased the expression of β-oxidation-associated enzymes in peroxisomes and auxiliary enzymes required for degradation, via the β-oxidation pathway, of unsaturated fatty acids in mitochondria. The ingestion of Sesamin also resulted in an increase in the gene expression of acyl-CoA thioesterase involved in acyl-CoA hydrolase and very-long-chain acyl-CoA thioesterase. Interestingly, it induced the expression of the gene for aldehyde dehydrogenase, an alcohol-metabolizing enzyme. ...
-
antioxidative roles of Sesamin a functional lignan in sesame seed and it s effect on lipid and alcohol metabolism in the liver a dna microarray study
Biofactors, 2004Co-Authors: Yoshinobu KisoAbstract:Sesamin was orally administered to rats, and blood, bile and urine were collected periodically. Over 40% of the dose of Sesamin was detected in bile as glucuronides of 2-(3, 4-methylenedioxyphenyl)-6-(3, 4-dihydroxyphenyl)-cis-dioxabicyclo[3.3.0] octane and 2-(3, 4-dihydroxyphenyl)-6-(3, 4-dihydroxyphenyl)-cis-dioxabicyclo[3.3.0] octane by 24 hr after administration. Antioxidant activities of these metabolites were compared and catechol metabolites showed strong radical scavenging activities against not only superoxide anion radical but also hydroxyl radical. It was suggested that Sesamin was absorbed by the route of portal vein and metabolized to mono- or di-catechol metabolite by drug metabolizing enzymes in the liver cells. Both metabolites exhibited antioxidant activity in the liver and were finally conjugated with glucuronic acid and to excrete in bile. Sesamin can be classified as a pro-antioxidant. The profiles of gene expression of the liver in rats given Sesamin or vehicle were compared. The gene expression levels of the late stage enzymes of beta-oxidation including trifunctional enzyme, acyl-CoA oxidase, bifunctional enzyme and 3-ketoacyl-CoA thiolase were significantly increased by Sesamin. On the other hand, the transcription of the genes encoding the enzymes for fatty acid synthesis was decreased. Moreover, in Sesamin rats, the gene expression of aldehyde dehydrogenase was increased about 3-fold, whereas alcohol dehydrogenase, liver catalase and CYP2E1 were not changed. These results suggested that Sesamin ingestion regulated the transcription levels of hepatic metabolizing enzymes for lipids and alcohol.
Toshiaki Hitomi - One of the best experts on this subject based on the ideXlab platform.
-
Sesamin a lignan of sesame down regulates cyclin d1 protein expression in human tumor cells
Cancer Science, 2007Co-Authors: Tomoya Yokota, Youichirou Matsuzaki, Mayumi Kawanaka, Masako Enokikonishi, Junko Takayasu, Makoto Koyama, Toshiaki Hitomi, Yusuke Okuyama, Hoyoku Nishino, Akiyoshi NishikawaAbstract:Sesamin is a major lignan constituent of sesame and possesses multiple functions such as antihypertensive, cholesterol-lowering, lipid-lowering and anticancer activities. Several groups have previously reported that Sesamin induces growth inhibition in human cancer cells. However, the nature of this growth inhibitory mechanism remains unknown. The authors here report that Sesamin induces growth arrest at the G1 phase in cell cycle progression in the human breast cancer cell line MCF-7. Furthermore, Sesamin dephosphorylates tumor-suppressor retinoblastoma protein (RB). It is also shown that inhibition of MCF-7 cell proliferation by Sesamin is correlated with down-regulated cyclin D1 protein expression, a proto-oncogene that is overexpressed in many human cancer cells. It was found that Sesamin-induced down-regulation of cyclin D1 was inhibited by proteasome inhibitors, suggesting that Sesamin suppresses cyclin D1 protein expression by promoting proteasome degradation of cyclin D1 protein. Sesamin down-regulates cyclin D1 protein expression in various kinds of human tumor cells, including lung cancer, transformed renal cells, immortalized keratinocyte, melanoma and osteosarcoma. Furthermore, depletion of cyclin D1 protein using small interfering RNA rendered MCF-7 cells insensitive to the growth inhibitory effects of Sesamin, implicating that cyclin D1 is at least partially related to the antiproliferative effects of Sesamin. Taken together, these results suggest that the ability of Sesamin to down-regulate cyclin D1 protein expression through the activation of proteasome degradation could be one of the mechanisms of the antiproliferative activity of this agent. (Cancer Sci 2007; 98: 1447–1453)
-
Sesamin a lignan of sesame down regulates cyclin d1 protein expression in human tumor cells
Cancer Science, 2007Co-Authors: Tomoya Yokota, Youichirou Matsuzaki, Mayumi Kawanaka, Masako Enokikonishi, Junko Takayasu, Makoto Koyama, Toshiaki Hitomi, Yusuke Okuyama, Hoyoku Nishino, Akiyoshi NishikawaAbstract:Sesamin is a major lignan constituent of sesame and possesses multiple functions such as antihypertensive, cholesterol-lowering, lipid-lowering and anticancer activities. Several groups have previously reported that Sesamin induces growth inhibition in human cancer cells. However, the nature of this growth inhibitory mechanism remains unknown. The authors here report that Sesamin induces growth arrest at the G1 phase in cell cycle progression in the human breast cancer cell line MCF-7. Furthermore, Sesamin dephosphorylates tumor-suppressor retinoblastoma protein (RB). It is also shown that inhibition of MCF-7 cell proliferation by Sesamin is correlated with down-regulated cyclin D1 protein expression, a proto-oncogene that is overexpressed in many human cancer cells. It was found that Sesamin-induced down-regulation of cyclin D1 was inhibited by proteasome inhibitors, suggesting that Sesamin suppresses cyclin D1 protein expression by promoting proteasome degradation of cyclin D1 protein. Sesamin down-regulates cyclin D1 protein expression in various kinds of human tumor cells, including lung cancer, transformed renal cells, immortalized keratinocyte, melanoma and osteosarcoma. Furthermore, depletion of cyclin D1 protein using small interfering RNA rendered MCF-7 cells insensitive to the growth inhibitory effects of Sesamin, implicating that cyclin D1 is at least partially related to the antiproliferative effects of Sesamin. Taken together, these results suggest that the ability of Sesamin to down-regulate cyclin D1 protein expression through the activation of proteasome degradation could be one of the mechanisms of the antiproliferative activity of this agent.
Hoyoku Nishino - One of the best experts on this subject based on the ideXlab platform.
-
Sesamin a lignan of sesame down regulates cyclin d1 protein expression in human tumor cells
Cancer Science, 2007Co-Authors: Tomoya Yokota, Youichirou Matsuzaki, Mayumi Kawanaka, Masako Enokikonishi, Junko Takayasu, Makoto Koyama, Toshiaki Hitomi, Yusuke Okuyama, Hoyoku Nishino, Akiyoshi NishikawaAbstract:Sesamin is a major lignan constituent of sesame and possesses multiple functions such as antihypertensive, cholesterol-lowering, lipid-lowering and anticancer activities. Several groups have previously reported that Sesamin induces growth inhibition in human cancer cells. However, the nature of this growth inhibitory mechanism remains unknown. The authors here report that Sesamin induces growth arrest at the G1 phase in cell cycle progression in the human breast cancer cell line MCF-7. Furthermore, Sesamin dephosphorylates tumor-suppressor retinoblastoma protein (RB). It is also shown that inhibition of MCF-7 cell proliferation by Sesamin is correlated with down-regulated cyclin D1 protein expression, a proto-oncogene that is overexpressed in many human cancer cells. It was found that Sesamin-induced down-regulation of cyclin D1 was inhibited by proteasome inhibitors, suggesting that Sesamin suppresses cyclin D1 protein expression by promoting proteasome degradation of cyclin D1 protein. Sesamin down-regulates cyclin D1 protein expression in various kinds of human tumor cells, including lung cancer, transformed renal cells, immortalized keratinocyte, melanoma and osteosarcoma. Furthermore, depletion of cyclin D1 protein using small interfering RNA rendered MCF-7 cells insensitive to the growth inhibitory effects of Sesamin, implicating that cyclin D1 is at least partially related to the antiproliferative effects of Sesamin. Taken together, these results suggest that the ability of Sesamin to down-regulate cyclin D1 protein expression through the activation of proteasome degradation could be one of the mechanisms of the antiproliferative activity of this agent. (Cancer Sci 2007; 98: 1447–1453)
-
Sesamin a lignan of sesame down regulates cyclin d1 protein expression in human tumor cells
Cancer Science, 2007Co-Authors: Tomoya Yokota, Youichirou Matsuzaki, Mayumi Kawanaka, Masako Enokikonishi, Junko Takayasu, Makoto Koyama, Toshiaki Hitomi, Yusuke Okuyama, Hoyoku Nishino, Akiyoshi NishikawaAbstract:Sesamin is a major lignan constituent of sesame and possesses multiple functions such as antihypertensive, cholesterol-lowering, lipid-lowering and anticancer activities. Several groups have previously reported that Sesamin induces growth inhibition in human cancer cells. However, the nature of this growth inhibitory mechanism remains unknown. The authors here report that Sesamin induces growth arrest at the G1 phase in cell cycle progression in the human breast cancer cell line MCF-7. Furthermore, Sesamin dephosphorylates tumor-suppressor retinoblastoma protein (RB). It is also shown that inhibition of MCF-7 cell proliferation by Sesamin is correlated with down-regulated cyclin D1 protein expression, a proto-oncogene that is overexpressed in many human cancer cells. It was found that Sesamin-induced down-regulation of cyclin D1 was inhibited by proteasome inhibitors, suggesting that Sesamin suppresses cyclin D1 protein expression by promoting proteasome degradation of cyclin D1 protein. Sesamin down-regulates cyclin D1 protein expression in various kinds of human tumor cells, including lung cancer, transformed renal cells, immortalized keratinocyte, melanoma and osteosarcoma. Furthermore, depletion of cyclin D1 protein using small interfering RNA rendered MCF-7 cells insensitive to the growth inhibitory effects of Sesamin, implicating that cyclin D1 is at least partially related to the antiproliferative effects of Sesamin. Taken together, these results suggest that the ability of Sesamin to down-regulate cyclin D1 protein expression through the activation of proteasome degradation could be one of the mechanisms of the antiproliferative activity of this agent.